India’s Bharat Enters Zika Fray With Two Vaccine Candidates
This article was originally published in PharmAsia News
Executive Summary
India's Bharat Biotech says it is working on two vaccines to tackle the rapidly spreading Zika virus, one of which is ready for preclinical trials.
You may also be interested in...
Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.